Chapter 24 — Vasoactive Peptide Pharmacology — Module 2 — ARBs, Natriuretic Peptides, and Sacubitril-Valsartan Tier: T3 (Clinical Vignette)
1. A 66-year-old man with HFrEF (ejection fraction 28%), NYHA class II symptoms, hypertension, and stage 3 CKD (eGFR 38 mL/min/1.73 m²) is referred for neurohormonal optimization. His medications include valsartan 160 mg twice daily, carvedilol 25 mg twice daily, and furosemide 40 mg daily. Blood pressure today is 97/62 mmHg. Chart review reveals a hospitalization four years ago for tongue swelling requiring emergency airway management that occurred two weeks after enalapril was started; enalapril was permanently discontinued. He has never received sacubitril-valsartan. His cardiologist considers initiating sacubitril-valsartan. Which of the following most accurately integrates all three clinical signals — blood pressure, renal function, and prior ACEi angioedema history — to determine the correct prescribing decision?
A) All three signals are cautions but none is an absolute contraindication; sacubitril-valsartan should be initiated at the lowest available dose of sacubitril 24 mg / valsartan 26 mg twice daily with close monitoring, because prior ACEi angioedema is a relative rather than absolute contraindication to sacubitril-valsartan, the SBP of 97 mmHg is managed by lowest-dose initiation, and eGFR of 38 mL/min/1.73 m² is above the dose-reduction threshold of 30 mL/min/1.73 m²
B) The SBP of 97 mmHg is the sole contraindication; sacubitril-valsartan should be held until blood pressure is optimized above 100 mmHg with furosemide dose reduction; the prior ACEi angioedema history does not affect ARNI eligibility because ARB-containing combinations do not raise bradykinin, and eGFR of 38 mL/min/1.73 m² requires no dose adjustment
C) The eGFR of 38 mL/min/1.73 m² is the primary concern; sacubitril-valsartan should not be initiated until eGFR recovers above 45 mL/min/1.73 m² because LBQ657 renal accumulation at this GFR level produces unpredictable AT1 receptor saturation; the prior ACEi angioedema is a relative caution that can be managed with prophylactic icatibant at initiation
D) Prior ACEi-induced angioedema — tongue swelling requiring emergency airway management — is an absolute contraindication to sacubitril-valsartan because the underlying heightened susceptibility to bradykinin-mediated vascular permeability persists regardless of which enzyme is inhibited; sacubitril inhibits neprilysin, which degrades bradykinin through a pathway distinct from ACE, and a patient with documented severe ACEi angioedema carries unacceptable angioedema risk with neprilysin inhibition; the correct agent is ARB monotherapy, which does not impair bradykinin clearance; the SBP and eGFR would have been manageable with lowest-dose ARNI initiation in the absence of this contraindication
E) No contraindication exists to sacubitril-valsartan in this patient; prior ACEi angioedema was caused by enalapril-specific ACE inhibition and does not predict risk from a drug that inhibits neprilysin rather than ACE; the patient should be transitioned from valsartan monotherapy to sacubitril-valsartan without washout at the lowest available dose given his blood pressure
ANSWER: D
Rationale:
Option D is correct. This question requires simultaneous integration of three clinical signals, and the prior ACEi angioedema history is decisive. Tongue swelling requiring emergency airway management is a severe manifestation of bradykinin-mediated angioedema — the most dangerous form, with laryngeal involvement risking fatal airway obstruction. The pharmacological basis of this risk with sacubitril-valsartan is that neprilysin degrades bradykinin through a peptide bond cleavage distinct from ACE; inhibiting neprilysin raises bradykinin through an independent enzymatic pathway. A patient who experienced severe ACEi angioedema has documented hypersensitivity of the bradykinin/B2 receptor/vascular permeability axis — a susceptibility that is pharmacologically independent of which enzyme is blocked. The sacubitril-valsartan prescribing information and current guidelines classify prior ACEi-induced angioedema as a contraindication to sacubitril-valsartan. PARADIGM-HF excluded this population entirely, so trial data do not establish a safe threshold for neprilysin inhibition in these patients. The correct neurohormonal agent is ARB monotherapy, which blocks AT1 receptors without inhibiting ACE or neprilysin and therefore does not impair bradykinin clearance by either pathway. The SBP of 97 mmHg would have indicated lowest-dose ARNI initiation, and eGFR of 38 mL/min/1.73 m² is above the LBQ657 accumulation threshold of 30 mL/min/1.73 m² — neither of these signals, alone or together, would have been absolute contraindications. The angioedema history overrides both.
Option A: Option A is incorrect. Prior ACEi-induced angioedema with severe laryngeal involvement is an absolute contraindication to sacubitril-valsartan, not a relative caution to be managed by dose selection. The pharmacological basis — neprilysin inhibition raising bradykinin through an independent pathway in a patient with documented extreme bradykinin susceptibility — does not become acceptable at a lower sacubitril dose; the pharmacodynamic risk is mechanism-based and not dose-titrated away.
Option B: Option B is incorrect. The statement that ARB-containing combinations do not raise bradykinin is accurate — ARBs do not inhibit ACE or neprilysin — but this accurately describes the valsartan component alone, not sacubitril-valsartan as a combination. The sacubitril component's neprilysin inhibition does raise bradykinin, and the prior ACEi angioedema history is a contraindication to that component's mechanism regardless of what the valsartan component does. The SBP and eGFR reasoning in this option is internally consistent but the conclusion to proceed with sacubitril-valsartan is wrong.
Option C: Option C is incorrect. LBQ657 accumulation at eGFR 38 mL/min/1.73 m² does not produce AT1 receptor saturation — LBQ657 inhibits neprilysin, not AT1 receptors, and the threshold for dose reduction (eGFR below 30 mL/min/1.73 m²) is not met at 38 mL/min/1.73 m². Prophylactic icatibant at ARNI initiation is not a standard clinical protocol for managing the angioedema contraindication, and this approach would not be acceptable in a patient with prior severe laryngeal angioedema.
Option E: Option E is incorrect. The claim that prior ACEi angioedema does not predict risk from neprilysin inhibition contradicts the established pharmacological basis of sacubitril-valsartan's angioedema risk: both ACEi and sacubitril raise bradykinin — through different enzymes — and a patient with documented severe susceptibility to bradykinin-mediated vascular permeability is at elevated risk from both mechanisms. The prescribing information explicitly lists prior ACEi angioedema as a contraindication.
2. A 74-year-old woman with HFrEF (ejection fraction 25%), NYHA class III symptoms, and no prior RAAS-blocking therapy is admitted for acute decompensated heart failure. After diuresis she is hemodynamically stable with blood pressure 98/64 mmHg, heart rate 72 bpm, weight at dry weight, and no rales. Creatinine is 1.9 mg/dL with eGFR 31 mL/min/1.73 m², potassium 4.2 mEq/L. She has no prior history of angioedema. Her cardiologist wishes to initiate sacubitril-valsartan before discharge. Which of the following correctly identifies whether she meets eligibility criteria for sacubitril-valsartan, the appropriate starting dose integrating all pharmacokinetic and hemodynamic factors, and the correct washout requirement?
A) She meets eligibility criteria for sacubitril-valsartan: HFrEF with ejection fraction well below 35%, symptomatic despite volume optimization, no prior angioedema, and eGFR of 31 mL/min/1.73 m² which, while at the lower boundary, is above the absolute contraindication threshold; the appropriate starting dose is sacubitril 24 mg / valsartan 26 mg twice daily, driven by three simultaneous low-dose indications: SBP below 100 mmHg, RAAS-naive status, and eGFR below 30 mL/min/1.73 m² requiring dose-adjusted initiation; no washout is required because she has received no prior ACEi or ARNI
B) She does not meet eligibility criteria because eGFR of 31 mL/min/1.73 m² falls below the PARADIGM-HF enrollment threshold of 45 mL/min/1.73 m², which constitutes a regulatory contraindication to sacubitril-valsartan; she should receive valsartan monotherapy until renal function improves above 45 mL/min/1.73 m² before ARNI initiation is reconsidered
C) She meets eligibility criteria; the appropriate starting dose is sacubitril 49 mg / valsartan 51 mg twice daily because the lowest available dose is reserved exclusively for patients with eGFR below 30 mL/min/1.73 m² and her eGFR of 31 mL/min/1.73 m² is technically above this threshold; a 36-hour washout is required from her current valsartan dose before starting sacubitril-valsartan
D) She meets eligibility criteria but sacubitril-valsartan should be deferred until outpatient follow-up at 4 to 6 weeks post-discharge because initiation of ARNI during a heart failure hospitalization carries a higher risk of in-hospital hypotension and AKI than outpatient initiation, and guidelines recommend against in-hospital ARNI initiation in RAAS-naive patients
E) She does not meet eligibility criteria because SBP of 98 mmHg is an absolute contraindication to any RAAS-blocking agent in a RAAS-naive patient; RAAS-naive patients have maximal angiotensin II-mediated vasoconstriction sustaining their blood pressure, and any RAAS blockade in this context risks hemodynamic collapse; she should receive carvedilol optimization first before any RAAS-blocking agent is introduced
ANSWER: A
Rationale:
Option A is correct. This patient meets all positive eligibility criteria for sacubitril-valsartan: HFrEF with ejection fraction of 25% (well within the HFrEF range), NYHA class III symptoms, no prior ACEi or ARNI angioedema, and potassium within the acceptable range at 4.2 mEq/L. The eGFR of 31 mL/min/1.73 m² is above the dose-adjustment threshold of 30 mL/min/1.73 m²; while eGFR below 30 mL/min/1.73 m² triggers lowest-dose initiation per the prescribing information, eGFR at 31 mL/min/1.73 m² is marginally above this threshold and does not constitute a contraindication. However, three concurrent lowest-dose indications apply: SBP of 98 mmHg (below 100 mmHg threshold), RAAS-naive status (higher baseline RAAS activation predicting greater vasodilatory response), and proximity to the renal dose-adjustment boundary with an eGFR that may fluctuate below 30 mL/min/1.73 m² — together these strongly favor starting at the lowest available dose of sacubitril 24 mg / valsartan 26 mg twice daily. No washout is required: the 36-hour washout applies only to transitions from ACEi (or from ARNI back to ACEi) and not to RAAS-naive initiation or ARB-to-ARNI transitions. In-hospital initiation is not contraindicated; evidence from registries and subgroup analyses supports pre-discharge initiation in stabilized patients with appropriate monitoring.
Option B: Option B is incorrect. The PARADIGM-HF enrollment minimum eGFR of 30 mL/min/1.73 m² (the trial criterion, not 45 mL/min/1.73 m²) is a trial design feature, not a regulatory contraindication. The sacubitril-valsartan prescribing information specifies dose adjustment at eGFR below 30 mL/min/1.73 m², not a contraindication at that threshold; eGFR of 31 mL/min/1.73 m² does not reach even the dose-adjustment threshold. The stated 45 mL/min/1.73 m² threshold is not a recognized prescribing criterion from any guideline or label.
Option C: Option C is incorrect on two counts. The lowest available dose is not reserved exclusively for eGFR below 30 mL/min/1.73 m²; it is indicated for any combination of SBP below 100 mmHg, volume depletion, high-dose diuretics, or RAAS-naive status — all of which apply here. Additionally, no washout is required from valsartan monotherapy to sacubitril-valsartan; the 36-hour washout applies only to ACEi-to-ARNI and ARNI-to-ACEi transitions, not ARB-to-ARNI transitions.
Option D: Option D is incorrect. Current evidence and guideline implementation support pre-discharge initiation of sacubitril-valsartan in hemodynamically stabilized HFrEF patients, including RAAS-naive patients, with appropriate dose selection and monitoring. Deferring to outpatient initiation when the patient has been optimized and meets criteria would unnecessarily delay a mortality-reducing therapy.
Option E: Option E is incorrect. SBP of 98 mmHg is not an absolute contraindication to RAAS-blocking agents; it is an indication for lowest-dose initiation and close monitoring. RAAS-naive patients do have higher baseline RAAS activation, but this is managed by starting at the lowest dose — not by withholding treatment. Sequencing carvedilol optimization before any RAAS blockade is not a guideline requirement and would delay initiation of a mortality-reducing neurohormonal agent without clinical justification.
3. A 71-year-old man with HFrEF on sacubitril-valsartan 97 mg/103 mg twice daily, carvedilol 25 mg twice daily, spironolactone 25 mg daily, and furosemide 80 mg daily presents to the emergency department with three days of worsening dyspnea, orthopnea, and ankle edema. Examination reveals elevated JVP (jugular venous pressure), bibasilar rales, and 3+ pitting edema. Vital signs: BP 84/52 mmHg, HR 104 bpm. Laboratory results: creatinine 2.4 mg/dL (baseline 1.6 mg/dL, a 50% increase), potassium 5.8 mEq/L (baseline 4.6 mEq/L), sodium 132 mEq/L. Which of the following most accurately triages which monitoring thresholds have been exceeded, which medications should be held, and the correct immediate management sequence?
A) Only the creatinine threshold has been exceeded; the 50% creatinine rise crosses the 30% acceptable limit; sacubitril-valsartan should be held and spironolactone continued because mineralocorticoid receptor antagonists protect against aldosterone-driven worsening renal injury during decompensation; the potassium of 5.8 mEq/L is within acceptable limits for a patient on spironolactone and does not require intervention
B) Multiple thresholds are simultaneously breached: creatinine rise of 50% exceeds the 30% acceptable threshold, potassium of 5.8 mEq/L exceeds the 5.5 mEq/L threshold for holding RAAS-blocking agents, and SBP of 84 mmHg indicates hemodynamic instability; sacubitril-valsartan, spironolactone, and carvedilol should all be held; the primary driver is decompensated heart failure with low-output physiology rather than ARNI toxicity, and IV diuresis is the urgent intervention to restore hemodynamics, after which medications can be reassessed for re-initiation at lower doses
C) The potassium of 5.8 mEq/L is the only exceeded threshold and is the sole indication to hold sacubitril-valsartan; the creatinine rise reflects appropriate efferent arteriolar dilation from AT1 blockade that is hemodynamically beneficial during decompensation, and carvedilol and spironolactone should be continued; oral kayexalate is sufficient potassium management and IV diuresis is not indicated because the patient has preserved kidney perfusion
D) No thresholds mandate drug discontinuation; the creatinine rise reflects dehydration from excess diuresis, not RAAS toxicity; furosemide should be reduced by 50% and sacubitril-valsartan continued at current dose; carvedilol and spironolactone are protective and should not be interrupted; the clinical picture is consistent with diuretic-induced prerenal azotemia, not hemodynamic decompensation
E) All medications should be held immediately and the patient should receive urgent right heart catheterization to measure filling pressures before any medication decisions are made; medication adjustments without hemodynamic data in a patient with multiple exceeded thresholds risk either undertreating a low-output state or overtreating a patient with adequate cardiac output who has iatrogenic volume depletion from excess furosemide
ANSWER: B
Rationale:
Option B is correct. This patient has multiple simultaneous threshold violations requiring systematic triage. The creatinine rise from 1.6 to 2.4 mg/dL represents a 50% increase — substantially exceeding the 30% acceptable threshold for RAAS-blocking agents. The potassium of 5.8 mEq/L exceeds the 5.5 mEq/L threshold above which RAAS-blocking agents should be held; this level also mandates urgent management given the risk of life-threatening hyperkalemia in the context of hemodynamic compromise. The SBP of 84 mmHg with tachycardia, elevated JVP, rales, and edema indicates decompensated low-output heart failure — not diuretic-induced volume depletion, which would produce reduced JVP and flat neck veins. The clinical picture is acute decompensation with volume overload and low cardiac output, likely precipitated by progressive heart failure rather than ARNI toxicity. Sacubitril-valsartan should be held (creatinine threshold exceeded, potassium threshold exceeded, SBP below threshold for ARNI continuation), spironolactone should be held (potassium 5.8 mEq/L is above the threshold for MRA continuation and its mineralocorticoid receptor antagonism is contributing to hyperkalemia), and carvedilol should be held (SBP 84 mmHg with low-output physiology contra-indicates negative chronotropy). Urgent IV diuresis is the hemodynamic intervention to reduce filling pressures and restore output. Medications should be reassessed for re-initiation once hemodynamics stabilize.
Option A: Option A is incorrect in classifying potassium of 5.8 mEq/L as within acceptable limits. The threshold for holding RAAS-blocking agents — including both sacubitril-valsartan and spironolactone — is 5.5 mEq/L; a potassium of 5.8 mEq/L clearly exceeds this and mandates holding spironolactone, not continuing it. Continuing spironolactone in the setting of potassium 5.8 mEq/L and hemodynamic compromise would worsen hyperkalemia and could precipitate fatal arrhythmia.
Option C: Option C is incorrect in minimizing the clinical situation. A 50% creatinine rise is not within the acceptable threshold. The interpretation that creatinine rise during decompensation reflects hemodynamically beneficial efferent arteriolar dilation from AT1 blockade misapplies the physiology of stable RAAS therapy to an acute low-output state where renal hypoperfusion, not therapeutic efferent dilation, is driving the creatinine rise. Oral kayexalate for potassium of 5.8 mEq/L in a hemodynamically compromised patient is insufficient and too slow; and withholding IV diuresis in a patient with rales, elevated JVP, and edema is incorrect.
Option D: Option D is incorrect. The clinical findings — elevated JVP, bilateral rales, and 3+ pitting edema — are inconsistent with diuretic-induced volume depletion and are consistent with decompensated volume overload. A creatinine rise of 50% in this hemodynamic context reflects cardiorenal syndrome from low cardiac output, not prerenal azotemia from diuresis. Reducing furosemide and continuing all medications would worsen the decompensation.
Option E: Option E is incorrect. Right heart catheterization is not the immediate priority in a patient with clinical signs of decompensation (elevated JVP, rales, edema, SBP 84 mmHg) who has clear indications for urgent IV diuresis. Clinical assessment is sufficient to guide immediate management; deferring medication decisions pending invasive hemodynamic data would cause dangerous treatment delay in a patient with multiple exceeded thresholds and hemodynamic instability.
4. A 68-year-old woman with hypertension, type 2 diabetes, and paroxysmal atrial fibrillation is on losartan 100 mg daily for blood pressure control and renoprotection. Her cardiologist initiates amiodarone for rhythm control. Six weeks later her home blood pressure log shows readings consistently 20 to 30 mmHg above her prior baseline despite full adherence. Renal function and electrolytes are unchanged. Pharmacogenomic testing reveals she is a CYP2C9 intermediate metabolizer at baseline. Which of the following most accurately integrates the amiodarone-losartan interaction with her underlying pharmacogenomic status to explain the blood pressure deterioration and the optimal management?
A) Amiodarone induces CYP2C9, increasing conversion of losartan to EXP3174 above therapeutic levels; combined with her intermediate metabolizer status generating higher baseline EXP3174 than an extensive metabolizer, the result is supratherapeutic AT1 blockade causing reflex renin release that overcomes the antihypertensive effect; the correct response is to reduce losartan to 50 mg daily
B) Amiodarone inhibits CYP3A4, which is responsible for EXP3174 elimination; EXP3174 accumulates to supratherapeutic concentrations, causing paradoxical AT1 receptor desensitization from chronic receptor occupation; substituting irbesartan eliminates the interaction because irbesartan is not metabolized by CYP3A4
C) Amiodarone is a potent CYP2C9 inhibitor; in a patient who is already a CYP2C9 intermediate metabolizer, amiodarone's CYP2C9 inhibition further impairs the hepatic conversion of losartan to its active metabolite EXP3174, reducing AT1 receptor blockade well below what the losartan dose would achieve in an unimpaired patient; the combination of a pharmacogenomically reduced baseline CYP2C9 activity compounded by pharmacological CYP2C9 inhibition produces clinically significant loss of antihypertensive efficacy; the correct management is to substitute a non-CYP2C9-dependent ARB such as valsartan, olmesartan, or irbesartan
D) The blood pressure deterioration is caused by amiodarone's direct AT1 receptor agonism; amiodarone shares structural homology with angiotensin II at the AT1 binding domain and competitively displaces losartan from the receptor; the correct management is to increase losartan to 150 mg daily to outcompete amiodarone's receptor occupancy
E) Amiodarone inhibits renal OAT3 (organic anion transporter 3), reducing losartan tubular secretion and paradoxically increasing losartan systemic exposure; however, because losartan itself has low AT1 affinity, the higher losartan concentration does not compensate for the EXP3174 deficiency caused by simultaneous CYP3A4 induction; switching to a loop diuretic for blood pressure control is appropriate while amiodarone continues
ANSWER: C
Rationale:
Option C is correct. This vignette requires integrating two simultaneous mechanisms acting on the same enzymatic pathway. Amiodarone is a broad CYP enzyme inhibitor with particularly strong inhibition of CYP2C9 and CYP2D6; its CYP2C9 inhibition reduces the hepatic conversion of losartan to EXP3174, its pharmacologically active metabolite with 10- to 40-fold greater AT1 receptor affinity than the parent compound. This patient is additionally a CYP2C9 intermediate metabolizer at baseline, meaning her CYP2C9 capacity was already reduced before amiodarone was started. The pharmacokinetic consequence of adding a potent CYP2C9 inhibitor to a CYP2C9 intermediate metabolizer is a compounding deficit: her already-reduced baseline EXP3174 generation is further impaired by pharmacological inhibition, producing a degree of EXP3174 deficiency substantially greater than either factor alone would cause in an extensive metabolizer. The accumulated losartan parent compound has insufficient AT1 affinity to compensate, and blood pressure control deteriorates in proportion to the loss of EXP3174-mediated receptor blockade. The pharmacokinetically rational management is to substitute an ARB that does not depend on CYP2C9 for its antihypertensive activity — valsartan, olmesartan, irbesartan, or candesartan are all appropriate alternatives, as none requires CYP2C9-mediated activation.
Option A: Option A is incorrect. Amiodarone is a CYP inhibitor, not an inducer; CYP2C9 induction would increase EXP3174 generation and could enhance rather than reduce blood pressure control. The described mechanism of supratherapeutic AT1 blockade causing reflex renin release overcomes the antihypertensive effect is pharmacologically implausible — reflex renin release in the setting of excess AT1 blockade would generate angiotensin I, but without AT1 activation (which is blocked), renin alone does not drive blood pressure.
Option B: Option B is incorrect. The primary CYP pathway for EXP3174 elimination is not CYP3A4-dominant in a clinically relevant way that produces EXP3174 accumulation. Amiodarone does inhibit CYP3A4, but the dominant interaction with losartan is through CYP2C9 inhibition impairing EXP3174 generation, not CYP3A4 inhibition causing EXP3174 accumulation. AT1 receptor desensitization from chronic EXP3174 excess is not an established clinical phenomenon explaining loss of blood pressure control.
Option D: Option D is incorrect. Amiodarone does not possess AT1 receptor agonist activity or share structural homology with angiotensin II. Amiodarone's primary pharmacological mechanisms are sodium and potassium channel blockade (class III antiarrhythmic) along with alpha- and beta-adrenergic receptor blockade; competitive AT1 receptor displacement by amiodarone has no pharmacological basis.
Option E: Option E is incorrect. The primary mechanism of the amiodarone-losartan interaction is CYP2C9 inhibition reducing EXP3174 generation, not renal transporter inhibition elevating losartan exposure. Switching to a loop diuretic as a substitute for RAAS blockade would be inappropriate: the patient has diabetic nephropathy requiring ARB-based renoprotection, and substituting a diuretic does not address either the antihypertensive or the renoprotective indication for RAAS blockade.
5. A 67-year-old man with HFrEF on sacubitril-valsartan 97 mg/103 mg twice daily for nine months presents for a routine follow-up. He reports stable functional status with NYHA class II symptoms, no orthopnea, and unchanged exercise tolerance. His weight is at dry weight. Blood pressure is 112/72 mmHg. A covering physician who is unfamiliar with the patient's medication list orders both BNP and NT-proBNP (N-terminal pro-B-type natriuretic peptide) to assess cardiac status. Results: BNP 540 pg/mL, NT-proBNP 780 pg/mL (age-adjusted threshold for this 67-year-old: 900 pg/mL). The covering physician interprets the BNP as diagnostic of decompensation and plans admission for IV diuresis. The patient's cardiologist, reached by phone, disagrees. Which of the following most accurately explains the discordance between the two biomarkers, identifies the pharmacological basis for interpreting each, and determines the correct clinical action?
A) The discordance reflects assay interference from sacubitril-valsartan metabolites cross-reacting with the BNP immunoassay antibody; both biomarkers are unreliable in patients on sacubitril-valsartan and neither should be used for monitoring heart failure status; the cardiologist should order a troponin and echocardiogram instead to assess cardiac status without biomarker confounding
B) The NT-proBNP of 780 pg/mL exceeds the threshold and is the valid biomarker, confirming decompensation; the low BNP relative to NT-proBNP reflects sacubitril's neprilysin inhibition reducing BNP production (not degradation) in proportion to improved hemodynamics; the covering physician should proceed with IV diuresis based on the NT-proBNP result
C) Both biomarkers are equally valid in sacubitril-treated patients; the BNP of 540 pg/mL and NT-proBNP of 780 pg/mL are concordant and both indicate mild hemodynamic stress requiring intensification of oral diuretic therapy by 50% without hospitalization; the covering physician's plan for IV diuresis is excessive but some diuretic adjustment is appropriate
D) The discordance reflects renal impairment selectively elevating NT-proBNP while sacubitril's neprilysin inhibition selectively elevates BNP; because this patient has two confounding variables affecting different biomarkers, neither result is interpretable and the patient should undergo right heart catheterization to obtain unconfounded hemodynamic data
E) BNP is a direct neprilysin substrate; sacubitril-mediated neprilysin inhibition impairs BNP degradation and causes BNP to rise artifactually — the BNP of 540 pg/mL cannot be interpreted as evidence of decompensation in this patient; NT-proBNP is not a neprilysin substrate, is unaffected by sacubitril, and remains a valid hemodynamic biomarker; the NT-proBNP of 780 pg/mL does not exceed the age-adjusted threshold of 900 pg/mL for this 67-year-old patient, and in the context of stable clinical examination, is not consistent with significant decompensation; the correct action is to observe and not admit for IV diuresis
ANSWER: E
Rationale:
Option E is correct. The discordance between BNP and NT-proBNP in a patient on sacubitril-valsartan is a direct pharmacological consequence of their differential relationships to neprilysin. BNP is a substrate for neprilysin; sacubitril inhibits neprilysin, impairing BNP degradation and causing BNP to accumulate at concentrations that exceed what ventricular wall stress alone would generate. The BNP of 540 pg/mL therefore cannot be interpreted using standard diagnostic thresholds in this patient — an unknown fraction of the elevation reflects enzymatic clearance impairment rather than hemodynamic stress. NT-proBNP (the N-terminal prohormone fragment) is not a neprilysin substrate; it is cleared by renal excretion and receptor-mediated pathways unaffected by sacubitril, and its plasma concentration accurately reflects ventricular wall stress. The NT-proBNP of 780 pg/mL must be interpreted against the age-appropriate threshold: for patients aged 50 to 75, the rule-out cutpoint is 900 pg/mL. This patient's NT-proBNP falls below the age-adjusted threshold at 780 pg/mL. In the context of a stable clinical examination — no orthopnea, dry weight maintained, NYHA class II stable, no elevated JVP or rales — this NT-proBNP result is not consistent with significant decompensation. The cardiologist is correct to decline admission for IV diuresis; the covering physician's error is applying a standard BNP threshold to a patient on neprilysin inhibitor therapy and ignoring the valid NT-proBNP result that does not support decompensation.
Option A: Option A is incorrect. BNP elevation in sacubitril-treated patients is not caused by immunoassay cross-reactivity with drug metabolites; it is a pharmacodynamic consequence of neprilysin inhibition reducing BNP enzymatic degradation. NT-proBNP remains a valid and reliable monitoring biomarker in sacubitril-treated patients precisely because it is not a neprilysin substrate. Neither biomarker is rendered unreliable by assay interference; the issue is correct interpretation, not technical assay failure.
Option B: Option B is incorrect. Sacubitril's neprilysin inhibition does not reduce BNP production; it reduces BNP degradation, causing BNP to rise, not fall, relative to the patient's true hemodynamic state. The higher BNP relative to NT-proBNP is the expected pharmacological finding in a neprilysin-inhibited patient. Additionally, the NT-proBNP of 780 pg/mL does not exceed the age-adjusted threshold of 900 pg/mL for a 67-year-old patient, so the NT-proBNP result does not confirm decompensation.
Option C: Option C is incorrect. BNP and NT-proBNP are not equally valid in sacubitril-treated patients; BNP is pharmacologically confounded by neprilysin inhibition and should not be used. The claim that both biomarkers indicate mild hemodynamic stress and warrant diuretic intensification is not supported by the valid NT-proBNP result, which falls below the age-adjusted diagnostic threshold, or by the stable clinical examination.
Option D: Option D is incorrect. There is no evidence that sacubitril selectively reduces NT-proBNP while renal impairment selectively elevates BNP in a way that creates a two-variable confounding scenario requiring invasive hemodynamic measurement. NT-proBNP is renally cleared and does rise with CKD (chronic kidney disease) independently of cardiac status, but the age-stratified cutpoints partially account for this, and the clinical picture here is stable. Right heart catheterization is not indicated based on the available clinical and biomarker data.
6. A 73-year-old woman with HFrEF (ejection fraction 30%), stage 3 CKD (eGFR 36 mL/min/1.73 m²), and primary hyperaldosteronism controlled on spironolactone 50 mg daily is being considered for transition from enalapril to sacubitril-valsartan. Her cardiologist asks the pharmacist to trace the pharmacodynamic interaction cascade between sacubitril-valsartan and spironolactone in the setting of CKD and identify the monitoring parameter that requires the most frequent early assessment. Which of the following most accurately predicts the interaction cascade and the highest-priority monitoring parameter?
A) The primary interaction is pharmacokinetic: spironolactone inhibits CYP3A4, reducing LBQ657 metabolism and causing neprilysin inhibitor accumulation; the highest-priority monitoring parameter is LBQ657 plasma concentration, measured at 2 weeks post-initiation to ensure it remains within the therapeutic range before uptitration is considered
B) Sacubitril-valsartan and spironolactone do not interact pharmacodynamically because they act on mechanistically independent axes — neprilysin inhibition and aldosterone receptor blockade respectively; in CKD, both drugs are renally cleared and their combined renal clearance impairment is the only relevant interaction, making creatinine the highest-priority monitoring parameter
C) The interaction cascade runs from sacubitril-valsartan's AT1 blockade reducing angiotensin II-stimulated aldosterone secretion → lower aldosterone production → reduced mineralocorticoid receptor activation → diminished aldosterone-driven potassium excretion → combined with spironolactone's further aldosterone receptor blockade and CKD-impaired potassium excretion, the cascade converges on hyperkalemia; however, the combination is guideline-supported and the monitoring priority is sodium, which falls more rapidly than potassium from combined natriuretic peptide and aldosterone axis suppression
D) The interaction cascade proceeds through two convergent pathways to hyperkalemia: sacubitril-valsartan's valsartan component blocks AT1 receptors, reducing angiotensin II-stimulated aldosterone secretion and thereby reducing aldosterone-driven renal potassium excretion; simultaneously, spironolactone blocks mineralocorticoid receptors in the collecting duct, directly impairing what aldosterone-driven potassium excretion remains; CKD compounds both pathways by reducing baseline renal potassium excretion capacity; the convergent result is additive hyperkalemia risk that is substantially amplified in CKD; the highest-priority monitoring parameter is serum potassium, measured at baseline, one to two weeks after initiation, and after each dose titration
E) The most clinically significant interaction is hypotension: sacubitril-valsartan produces vasodilation through both neprilysin inhibition (elevated ANP and BNP) and AT1 blockade, while spironolactone produces natriuresis reducing preload; the combined volume-depleting and vasodilatory effects in a CKD patient with reduced cardiovascular reserve produce orthostatic hypotension as the dominant risk; potassium and creatinine monitoring are secondary; blood pressure is the highest-priority monitoring parameter at each visit
ANSWER: D
Rationale:
Option D is correct. This question requires tracing a multi-step pharmacodynamic cascade through two converging pathways to identify the dominant clinical risk and most urgent monitoring priority. The first pathway: sacubitril-valsartan's valsartan component blocks AT1 receptors on adrenal zona glomerulosa cells, eliminating angiotensin II-mediated stimulation of aldosterone synthase and substantially reducing aldosterone secretion; reduced aldosterone means reduced ENaC (epithelial sodium channel) activation and reduced ROMK (renal outer medullary potassium channel) expression in the collecting duct principal cell, reducing potassium excretion. The second pathway: spironolactone competitively antagonizes the mineralocorticoid receptor in the same collecting duct principal cell, blocking whatever aldosterone-driven potassium excretion remains after AT1 blockade reduces aldosterone; even low residual aldosterone cannot activate its receptor in the presence of spironolactone. CKD amplifies both pathways by reducing the baseline GFR-dependent potassium filtered load and tubular flow available for excretion. The three factors — AT1 blockade reducing aldosterone production, spironolactone blocking residual aldosterone action, and CKD limiting baseline excretion capacity — converge to produce additive, potentially synergistic hyperkalemia risk. Serum potassium is the highest-priority monitoring parameter, measured at baseline before initiation, at one to two weeks post-initiation, and after each dose titration step. The 36-hour ACEi washout applies before starting sacubitril-valsartan; enalapril must be discontinued and 36 hours must elapse before the first dose.
Option A: Option A is incorrect. Spironolactone does not inhibit CYP3A4 to a clinically significant degree; it is primarily metabolized by CYP3A4, not an inhibitor of it. LBQ657 plasma concentration monitoring is not a standard clinical practice; drug monitoring for sacubitril-valsartan is based on clinical parameters (blood pressure, renal function, potassium) rather than pharmacokinetic drug level measurement.
Option B: Option B is incorrect. Sacubitril-valsartan and spironolactone interact pharmacodynamically through a well-defined convergent pathway to hyperkalemia, as described in the correct answer. The claim that their mechanisms are independent and non-interacting overlooks the shared final pathway of reduced renal potassium excretion. While creatinine monitoring is important, it is not the highest-priority parameter given the additive hyperkalemia risk from three simultaneous contributors in this patient.
Option C: Option C is incorrect. Although it traces the aldosterone-reduction pathway accurately in its opening steps, it misidentifies sodium as the highest-priority monitoring parameter and claims sodium falls more rapidly than potassium from combined natriuretic peptide and aldosterone suppression. The dominant early risk from AT1 blockade plus mineralocorticoid receptor antagonism plus CKD is hyperkalemia, not hyponatremia; guideline monitoring protocols for this drug combination specifically mandate early potassium measurement, not sodium-first monitoring.
Option E: Option E is incorrect in identifying hypotension as the dominant risk and blood pressure as the highest-priority monitoring parameter over potassium in this specific combination. While hypotension is a relevant concern with sacubitril-valsartan initiation and is addressed by lowest-dose initiation, the combination of AT1 blockade, mineralocorticoid receptor antagonism, and CKD creates a specific additive hyperkalemia risk that the AHA/ACC/HFSA guidelines identify as requiring most urgent early laboratory monitoring. Blood pressure is monitored at each visit but does not require the same early post-initiation laboratory frequency as potassium.
7. A pediatric endocrinologist asks a clinical pharmacologist why vosoritide, a CNP (C-type natriuretic peptide) analog approved for achondroplasia, successfully increases linear bone growth in children with FGFR3 (fibroblast growth factor receptor 3) gain-of-function mutations, while sacubitril-valsartan — which also raises circulating CNP by inhibiting neprilysin-mediated CNP degradation — does not produce any measurable skeletal benefit in patients with achondroplasia or normal individuals. The pharmacologist explains that this comparison illuminates a fundamental principle of paracrine pharmacology. Which of the following most accurately traces the biological and pharmacokinetic reasoning that accounts for vosoritide's efficacy and sacubitril's failure to replicate it at the growth plate?
A) CNP exerts its growth plate effects as a paracrine mediator: it is synthesized locally by chondrocytes and perichondrial cells within the growth plate and acts on NPR-B receptors on adjacent chondrocytes in the same avascular microenvironment; the growth plate does not receive systemic blood supply in its active proliferative zone, and local CNP concentrations are determined by local synthesis and local neprilysin activity in the perichondrium, not by circulating CNP; sacubitril raises systemic CNP by inhibiting neprilysin in renal tubular cells, pulmonary endothelium, and systemic vasculature, but cannot meaningfully raise CNP within the avascular growth plate compartment because the drug has no route of delivery to that tissue; vosoritide, a pegylated CNP analog administered subcutaneously with extended plasma half-life, achieves sustained supraphysiological NPR-B agonism by diffusing from the systemic circulation into the perichondrium at concentrations sufficient to activate NPR-B on chondrocytes — a pharmacokinetic advantage that sacubitril's indirect mechanism cannot replicate through systemic neprilysin inhibition
B) Vosoritide works because it directly inhibits FGFR3 tyrosine kinase activity through a CNP structural domain that mimics the FGF binding interface; sacubitril raises endogenous CNP but endogenous CNP lacks the FGFR3-inhibitory domain that was engineered into vosoritide; the distinction is structural rather than pharmacokinetic, and a higher dose of sacubitril would still fail because the endogenous CNP it raises cannot structurally inhibit FGFR3
C) The growth plate chondrocyte expresses NPR-A rather than NPR-B; vosoritide was misclassified as a CNP analog and actually acts as a high-affinity NPR-A agonist with 1000-fold selectivity over NPR-B; sacubitril raises CNP which signals through NPR-B, but the therapeutic target in achondroplasia is NPR-A and sacubitril raises the wrong natriuretic peptide for this receptor
D) Vosoritide is effective because it undergoes renal tubular secretion that concentrates it in the growth plate's perivascular supply vessels; this renal concentration mechanism allows vosoritide to achieve local growth plate concentrations 50-fold higher than plasma; sacubitril cannot be concentrated by this mechanism because LBQ657 is too large to be transported by OAT1 (organic anion transporter 1) and therefore distributes only to systemic compartments
E) The distinction is entirely pharmacodynamic rather than pharmacokinetic: vosoritide is a full NPR-B agonist while CNP raised by sacubitril is a partial agonist at the same receptor; the partial agonism of endogenous CNP produces insufficient cGMP (cyclic guanosine monophosphate) signal intensity at the NPR-B receptor to antagonize constitutively overactive FGFR3 signaling in achondroplastic chondrocytes, while vosoritide's full agonism generates cGMP above the threshold needed for FGFR3 pathway suppression
ANSWER: A
Rationale:
Option A is correct. The pharmacological principle illustrated by this comparison is the distinction between systemic drug delivery and paracrine signaling compartments. CNP functions as a paracrine mediator in the growth plate: it is synthesized locally by chondrocytes and perichondrial cells, acts on NPR-B receptors on adjacent chondrocytes within the same tissue, and its local concentration is regulated by local synthesis and local enzymatic degradation — principally by neprilysin expressed in the perichondrium and surrounding connective tissue. The proliferative zone of the growth plate cartilage is avascular; it does not receive direct systemic blood supply, and circulating molecules reach it only by diffusion from the perichondrial vasculature at the cartilage periphery. Sacubitril inhibits neprilysin in high-expression tissues — renal proximal tubular cells, pulmonary endothelium, and systemic vasculature — raising circulating CNP in the systemic compartment. However, this systemic CNP elevation does not meaningfully penetrate the avascular growth plate microenvironment where NPR-B activation is needed, because the drug's indirect mechanism (raising systemic CNP by blocking systemic neprilysin) cannot deliver therapeutic CNP concentrations to the paracrine compartment where CNP normally acts locally. Vosoritide, a pegylated CNP analog with an extended plasma half-life of approximately 30 minutes (versus endogenous CNP's 2-3 minutes), is administered subcutaneously and circulates at sustained supraphysiological concentrations that diffuse from the perichondrial vasculature into the adjacent growth plate tissue — achieving NPR-B agonism at concentrations that local endogenous CNP production in achondroplasia cannot reach against the constitutively overactive FGFR3 signal. The paracrine-versus-systemic distinction is the pharmacological principle that explains the differential efficacy.
Option B: Option B is incorrect. Vosoritide is a CNP analog that acts as an NPR-B agonist; it does not inhibit FGFR3 tyrosine kinase directly or contain a structural domain engineered for FGFR3 inhibition. The mechanism is NPR-B/cGMP/PKG (protein kinase G)-mediated antagonism of downstream FGFR3 signaling — an indirect pharmacodynamic interaction, not direct kinase inhibition. The distinction between vosoritide and sacubitril is pharmacokinetic (systemic delivery and diffusion into the growth plate compartment), not structural engineering of FGFR3-inhibitory domains.
Option C: Option C is incorrect. CNP signals through NPR-B, and NPR-B is expressed in growth plate chondrocytes and perichondrial cells — this is the established receptor-tissue distribution that underlies both vosoritide's mechanism and the pharmacological rationale for CNP/NPR-B in skeletal biology. Vosoritide is correctly classified as a CNP analog acting at NPR-B, not a misclassified NPR-A agonist. Loss-of-function mutations in NPR2 (the NPR-B gene) cause skeletal dysplasia, confirming that NPR-B, not NPR-A, is the therapeutically relevant receptor in this context.
Option D: Option D is incorrect. There is no established mechanism by which vosoritide undergoes renal tubular secretion concentrating it 50-fold in growth plate perivascular supply vessels; the growth plate cartilage in its proliferative zone is avascular and does not have its own perivascular supply vessels in the sense described. Vosoritide's pharmacokinetic advantage is its extended plasma half-life enabling sustained circulating concentrations that diffuse from the perichondrial vasculature, not renal tubular concentration.
Option E: Option E is incorrect. Endogenous CNP is a full NPR-B agonist, not a partial agonist; its intrinsic efficacy at NPR-B is not the limiting factor. The distinction between vosoritide's efficacy and sacubitril's failure is pharmacokinetic — the inability of systemic neprilysin inhibition to raise CNP concentrations within the avascular growth plate compartment — rather than a difference in agonist efficacy at the shared receptor.
8. A 69-year-old woman with HFpEF (ejection fraction 52%), NYHA class II-III symptoms, elevated NT-proBNP at 1,240 pg/mL, hypertension, obesity, and type 2 diabetes is currently managed on furosemide, amlodipine, and metformin. Her cardiologist considers initiating sacubitril-valsartan and asks a fellow to present the evidence basis and the current guideline recommendation. The fellow must accurately characterize the trial data, the relevant subgroup, and the guideline class before the cardiologist will order the drug. Which of the following most accurately fulfills this task?
A) PARAGON-HF demonstrated a statistically significant reduction in the primary composite endpoint in women with HFpEF but not in men; the current guideline gives sacubitril-valsartan a Class I, Level of Evidence B recommendation specifically for women with HFpEF based on this sex-specific subgroup result; this patient qualifies for Class I-indicated therapy and the drug should be initiated with a 36-hour washout from any prior ACEi
B) PARAGON-HF did not meet its primary composite endpoint for the overall HFpEF population (rate ratio 0.87; p=0.059); prespecified subgroup analyses suggested possible benefit in patients with ejection fraction below the trial median of approximately 57% and in women — both of which apply to this patient (EF 52%, female); current guidelines assign sacubitril-valsartan a Class IIb recommendation (may be considered) for HFmrEF and lower-range HFpEF based on this subgroup signal; the evidence is suggestive but not definitive, the guideline class is weaker than for HFrEF, and no washout is required since she has received no prior ACEi or ARNI
C) PARAGON-HF demonstrated that sacubitril-valsartan was inferior to valsartan alone for the primary endpoint in HFpEF; the current guidelines assign a Class III recommendation (harm) for sacubitril-valsartan in patients with ejection fraction above 50%; this patient's ejection fraction of 52% places her in the contraindicated range and the drug should not be prescribed
D) No large randomized controlled trial has evaluated sacubitril-valsartan in HFpEF; PARAGON-HF enrolled patients with HFrEF only, and the current guideline assigns no recommendation for sacubitril-valsartan in HFpEF because the evidence gap is complete; this patient should receive empiric ARB therapy while waiting for ongoing HFpEF trials to report
E) PARAGON-HF demonstrated equivalent benefit in men and women with HFpEF across the full ejection fraction range; the benefit was driven entirely by reduction in heart failure hospitalizations with no cardiovascular mortality effect; the current guideline gives sacubitril-valsartan a Class IIa recommendation (reasonable) for all HFpEF patients regardless of ejection fraction or sex based on the hospitalization reduction signal
ANSWER: B
Rationale:
Option B is correct. PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in Heart Failure with Preserved Ejection Fraction) enrolled 4,822 patients with HFpEF (ejection fraction at or above 45%), NYHA class II-IV symptoms, and elevated natriuretic peptides, randomized to sacubitril-valsartan versus valsartan. The primary composite endpoint of total heart failure hospitalizations and cardiovascular death was not statistically significant for the overall population (rate ratio 0.87; 95% CI 0.75–1.01; p=0.059). Two prespecified subgroup analyses showed numerically greater and statistically suggestive benefit: patients with ejection fraction below the trial median of approximately 57% (a group now classified as HFmrEF in updated nomenclature) and women. This patient has both characteristics: ejection fraction of 52% (below the 57% median) and female sex. The 2022 AHA/ACC/HFSA guidelines assign sacubitril-valsartan a Class IIb recommendation — "may be considered" — for patients with HFmrEF and for HFpEF patients with lower ejection fractions, reflecting the subgroup signal from PARAGON-HF without the definitive trial result that would support a Class I recommendation. The fellow must communicate that this is weaker evidence than for HFrEF, that the overall trial was negative, and that the recommendation is based on a subgroup signal. No washout is required as the patient has received no prior ACEi or ARNI; the transition from no RAAS-blocking agent to sacubitril-valsartan does not require a washout period.
Option A: Option A is incorrect. PARAGON-HF did not produce a statistically significant result for women specifically that would support a Class I, Level of Evidence B recommendation; the sex subgroup showed numerically greater benefit but the overall trial did not meet its primary endpoint and the sex interaction was prespecified but not definitive for regulatory or guideline purposes. The current guideline class for HFpEF/HFmrEF is IIb, not I. Additionally, the 36-hour washout applies to ACEi-to-ARNI transitions only; no washout is needed for a patient naive to both drug classes.
Option C: Option C is incorrect. PARAGON-HF did not demonstrate inferiority or harm from sacubitril-valsartan in HFpEF; it showed a numerically favorable but statistically non-significant trend. No Class III (harm) recommendation exists for sacubitril-valsartan in patients with ejection fraction above 50%; the guideline assigns no contraindication at any specific ejection fraction above the HFrEF range.
Option D: Option D is incorrect. PARAGON-HF enrolled patients with HFpEF (ejection fraction at or above 45%), not HFrEF; the trial is completed and published. Current guidelines do address sacubitril-valsartan for HFpEF/HFmrEF with a Class IIb recommendation based on PARAGON-HF subgroup data. The claim that no evidence or guideline recommendation exists for HFpEF is factually incorrect.
Option E: Option E is incorrect. PARAGON-HF did not demonstrate equivalent benefit across all ejection fractions or in both sexes; the numerical signal was concentrated in the lower-ejection-fraction and female subgroups. The guideline recommendation is Class IIb (may be considered), not Class IIa (reasonable), and it is not assigned to all HFpEF patients regardless of ejection fraction and sex.
9. A 64-year-old man with HFrEF on sacubitril-valsartan 97 mg/103 mg twice daily, furosemide 40 mg daily, and carvedilol 25 mg twice daily presents to the emergency department with an acutely swollen, erythematous first metatarsophalangeal joint consistent with acute gout. Creatinine is 1.3 mg/dL (baseline 1.1 mg/dL) and eGFR is 58 mL/min/1.73 m². The emergency physician plans to prescribe indomethacin 50 mg three times daily for five days. The patient's cardiologist, contacted for medication review, strongly objects. Which of the following most accurately predicts the pharmacodynamic interaction between indomethacin and the patient's existing medications and identifies the safest evidence-based analgesic alternative?
A) The cardiologist objects because indomethacin inhibits CYP3A4, reducing LBQ657 metabolism and causing neprilysin inhibitor accumulation that could amplify natriuretic peptide levels to the point of severe hypotension; the safest alternative is celecoxib, which does not inhibit CYP3A4 and does not interact with sacubitril's pharmacokinetics
B) The cardiologist objects because indomethacin's sodium retention effect from prostaglandin inhibition will cause acute fluid overload in an HFrEF patient on sacubitril-valsartan; the safest alternative is naproxen at the lowest dose because naproxen's longer half-life produces more gradual fluid retention that the furosemide dose can compensate for before hemodynamic decompensation occurs
C) The cardiologist objects because indomethacin inhibits COX (cyclooxygenase) enzymes in the renal cortex, eliminating prostaglandin-mediated afferent arteriolar vasodilation that is critical for maintaining glomerular perfusion in a patient whose efferent arteriolar tone is already reduced by sacubitril-valsartan's AT1 blockade; the combined loss of afferent vasodilatory support and efferent pressure maintenance creates the triple-whammy AKI pattern even without an ACEi — two of the three drugs implicated are present; the safest evidence-based alternative for acute gout in a patient on RAAS-blocking agents is colchicine, which does not affect renal prostaglandins or intraglomerular hemodynamics
D) The cardiologist objects because indomethacin is an absolute contraindication in any patient receiving a mineralocorticoid receptor antagonist due to the risk of fatal hyperkalemia from combined renal potassium retention; the safest alternative is a short course of oral prednisone, which does not interact with RAAS-blocking agents and produces no renal hemodynamic effects
E) The cardiologist objects because indomethacin inhibits the tubular secretion pathway shared by valsartan and LBQ657, raising plasma concentrations of both drug components to supratherapeutic levels; the safest alternative is acetaminophen, which has no renal hemodynamic effects and does not share the tubular secretion pathway with sacubitril-valsartan components
ANSWER: C
Rationale:
Option C is correct. This scenario does not include an ACEi, but it does include two of the three pharmacodynamic components of triple-whammy AKI: indomethacin would eliminate prostaglandin-mediated afferent arteriolar vasodilation (the first component), and sacubitril-valsartan's AT1 blockade by valsartan reduces angiotensin II-mediated efferent arteriolar constriction (the second component). The concurrent use of furosemide adds a third contribution by potentially reducing intravascular volume and further impairing renal perfusion pressure. Although a traditional ACEi is not present, the combination of NSAID plus ARB-containing RAAS blocker plus loop diuretic in a patient with already-marginal eGFR creates a hemodynamically analogous situation to the classic triple-whammy. The mechanism is precise: renal prostaglandins (PGE2 and PGI2) maintain afferent arteriolar tone in patients with reduced renal perfusion reserve — their elimination by indomethacin causes afferent vasoconstriction; simultaneously, valsartan removes angiotensin II-mediated efferent pressure, collapsing the transglomerular filtration gradient. The safest alternative analgesic for acute gout in this clinical context is colchicine: it inhibits tubulin polymerization and neutrophil migration to reduce gout-related inflammation through a mechanism entirely independent of prostaglandin synthesis or renal hemodynamics, carries no interaction with RAAS-blocking agents or loop diuretics, and does not impair glomerular filtration pressure.
Option A: Option A is incorrect. Indomethacin does not inhibit CYP3A4 to a clinically significant degree; the objection to indomethacin in this patient is pharmacodynamic (renal prostaglandin inhibition causing hemodynamic AKI), not pharmacokinetic. Celecoxib is a selective COX-2 inhibitor but still inhibits renal prostaglandin synthesis and carries the same hemodynamic renal risk as non-selective NSAIDs in patients on RAAS-blocking agents; it is not a safe alternative in this context.
Option B: Option B is incorrect. While NSAIDs do cause sodium and water retention through prostaglandin inhibition of the distal nephron, the primary and most acute risk in this patient is hemodynamic AKI from the pharmacodynamic interaction with RAAS blockade, not fluid overload. Naproxen inhibits renal prostaglandins by the same mechanism as indomethacin and carries equivalent hemodynamic AKI risk; it is not a safer NSAID alternative in a patient on sacubitril-valsartan and furosemide. The rationale that furosemide can compensate for naproxen's slower fluid retention is pharmacologically unsound.
Option D: Option D is incorrect. Indomethacin is not absolutely contraindicated in patients receiving mineralocorticoid receptor antagonists on the basis of fatal hyperkalemia; this patient is not on spironolactone. Short-course oral prednisone is a valid acute gout treatment but carries its own risks in HFrEF: fluid retention, sodium retention, and hyperglycemia from glucocorticoid effects; while sometimes used, colchicine is the preferred first-line acute gout treatment in cardiac patients specifically because it avoids these complications.
Option E: Option E is incorrect. Indomethacin's primary clinical risk in this patient is not tubular secretion competition with valsartan or LBQ657; it is prostaglandin inhibition causing renal hemodynamic compromise. Acetaminophen does not inhibit renal prostaglandin synthesis and has no renal hemodynamic effects, making it a safe analgesic for pain — but acetaminophen does not have meaningful anti-inflammatory efficacy for acute gout and would not adequately treat the acute inflammatory joint disease. Colchicine, with its targeted anti-inflammatory mechanism in gout, is the more appropriate alternative.
10. A 34-year-old woman was diagnosed with peripartum cardiomyopathy six months ago with initial ejection fraction of 22%. She was started on sacubitril-valsartan, carvedilol, and spironolactone and has done well. Today's echocardiogram shows ejection fraction recovered to 48%. She has no symptoms, no residual edema, and NT-proBNP is 180 pg/mL (within normal range for age). She asks her cardiologist whether she can stop sacubitril-valsartan now that her heart function has returned to normal. Which of the following most accurately integrates the evidence on ejection fraction recovery in peripartum cardiomyopathy, ongoing neurohormonal dependence, and current guideline recommendations to counsel this patient?
A) Ejection fraction recovery to 48% confirms complete myocardial healing and resolution of the underlying cardiomyopathy; all neurohormonal agents including sacubitril-valsartan, carvedilol, and spironolactone can be safely discontinued because continued RAAS blockade in a patient with normalized ejection fraction carries no mortality benefit and exposes her to drug-related adverse effects without justification
B) Sacubitril-valsartan should be continued indefinitely but carvedilol can be discontinued since ejection fraction recovery above 45% indicates that the sympathetic activation driving adverse cardiac remodeling has resolved; beta-blockers are indicated only for ejection fractions persistently below 40% and the current ejection fraction of 48% places her in the HFmrEF range where beta-blocker evidence is weak
C) Sacubitril-valsartan should be tapered over 12 weeks and discontinued; the drug was initiated for an acute cardiomyopathy and ejection fraction recovery to 48% meets the prespecified recovery endpoint used in peripartum cardiomyopathy trials to define remission; maintaining sacubitril-valsartan beyond remission carries proven harm from excess neurohormonal suppression causing sinus bradycardia and hypotension
D) Ejection fraction recovery to 48% is sufficient to discontinue sacubitril-valsartan immediately, but the patient should continue carvedilol and spironolactone indefinitely because beta-blocker and MRA (mineralocorticoid receptor antagonist) therapy are required for life in peripartum cardiomyopathy regardless of ejection fraction to prevent recurrence; sacubitril-valsartan is the only agent in this regimen without a lifelong indication
E) Ejection fraction recovery to 48% — while clinically encouraging — does not constitute grounds for discontinuing sacubitril-valsartan; guideline recommendations do not support stopping neurohormonal therapy based on ejection fraction normalization alone, because the myocardial substrate may remain vulnerable to recurrent dysfunction if RAAS-dependent remodeling is withdrawn; the recommended approach is to continue all neurohormonal agents for a minimum of one to two years after ejection fraction recovery in peripartum cardiomyopathy, with any medication changes made after a period of sustained stability and shared decision-making that incorporates future pregnancy planning, the risk of recurrence during subsequent pregnancies, and close hemodynamic monitoring during any planned dose reduction
ANSWER: E
Rationale:
Option E is correct. Ejection fraction recovery in peripartum cardiomyopathy is a favorable prognostic sign, but it does not represent resolution of the biological substrate that makes the myocardium susceptible to neurohormonal-driven adverse remodeling. Several lines of evidence support continuing neurohormonal therapy after ejection fraction recovery. First, premature discontinuation of neurohormonal agents in other forms of dilated cardiomyopathy — even after ejection fraction normalization — frequently leads to recurrent dysfunction; the myocardium may appear structurally normalized by echocardiographic ejection fraction while remaining dependent on RAAS suppression to maintain that function. Second, peripartum cardiomyopathy carries a specific and substantial risk of recurrence with subsequent pregnancies, each of which would require discontinuing sacubitril-valsartan; this makes any pre-pregnancy medication tapering a carefully structured process rather than an opportunistic withdrawal. Third, current guideline consensus recommends continuing neurohormonal therapy for at least one to two years after ejection fraction recovery in peripartum cardiomyopathy, with medication withdrawal only after a sustained period of stability, shared decision-making, and a structured plan for monitoring during and after dose reduction. An NT-proBNP of 180 pg/mL and normalized ejection fraction are reassuring but represent a single time point; continued therapy maintains the neurohormonal environment that supported recovery and protects against recurrent dysfunction during the most vulnerable post-recovery period.
Option A: Option A is incorrect. Discontinuing all neurohormonal agents at ejection fraction recovery is not guideline-supported in peripartum cardiomyopathy. The myocardium may remain neurohormonal-dependent despite apparent ejection fraction normalization, and premature discontinuation carries documented risk of recurrent cardiomyopathy. The claim that continued RAAS blockade carries no mortality benefit in a patient with normalized ejection fraction has not been established in peripartum cardiomyopathy, where the natural history and recurrence risk are distinct from other forms of cardiomyopathy.
Option B: Option B is incorrect. Current guidelines recommend continuing beta-blockers in peripartum cardiomyopathy after ejection fraction recovery; the evidence for beta-blocker benefit is not restricted to ejection fractions below 40%, and arbitrarily stopping carvedilol at ejection fraction of 48% is not guideline-concordant management. The HFmrEF classification (ejection fraction 41-49%) does not constitute evidence-free territory for beta-blockers in the specific context of recovering peripartum cardiomyopathy.
Option C: Option C is incorrect. No peripartum cardiomyopathy trial has established ejection fraction recovery to 48% as a prespecified endpoint triggering ARNI discontinuation, and no evidence exists that continuing sacubitril-valsartan after ejection fraction recovery causes harm through excess neurohormonal suppression producing sinus bradycardia. The taper-and-discontinue approach described is not supported by current clinical evidence or guideline recommendations.
Option D: Option D is incorrect. There is no pharmacological or guideline basis for discontinuing sacubitril-valsartan while continuing carvedilol and spironolactone indefinitely in this patient; all three agents are components of guideline-recommended neurohormonal therapy for HFrEF that should be continued in a structured, evidence-based manner after ejection fraction recovery in peripartum cardiomyopathy. Selectively discontinuing sacubitril-valsartan as the "only agent without a lifelong indication" does not reflect current evidence or prescribing guidance.
11. A 62-year-old man with HFrEF (ejection fraction 32%) on sacubitril-valsartan 97 mg/103 mg twice daily, carvedilol 25 mg twice daily, and furosemide 40 mg daily presents for a scheduled follow-up. He is clinically stable: no dyspnea at rest, mild exertional dyspnea unchanged from prior visits, no orthopnea, weight at his dry weight, blood pressure 108/70 mmHg, no peripheral edema, no elevated JVP. Creatinine is 1.7 mg/dL (eGFR 44 mL/min/1.73 m²; stable). His NT-proBNP today is 3,200 pg/mL. A medical student on the team notes that the NT-proBNP of 3,200 pg/mL is far above the age-adjusted threshold of 900 pg/mL for patients aged 50 to 75 and suggests urgent diuresis. The attending asks the student to integrate all available data before reaching a clinical conclusion. Which of the following most accurately integrates the biomarker result with the two major confounders present in this patient to determine the correct interpretation and clinical action?
A) The NT-proBNP of 3,200 pg/mL confirms significant hemodynamic decompensation that is not yet clinically apparent; subclinical decompensation detected by natriuretic peptide elevation precedes clinical signs by 48 to 72 hours and the student is correct to recommend urgent IV diuresis before overt fluid overload develops
B) The NT-proBNP of 3,200 pg/mL is artifactually elevated by sacubitril-valsartan therapy in the same way that BNP is elevated; both BNP and NT-proBNP are substrates for neprilysin, and sacubitril inhibition of neprilysin raises both biomarkers equally; neither is valid for monitoring heart failure status in sacubitril-treated patients and the student's concern about the NT-proBNP value is appropriate but the correct response is to switch to troponin monitoring
C) NT-proBNP of 3,200 pg/mL should trigger immediate echocardiography to assess whether ejection fraction has declined below the baseline of 32%; a fall in ejection fraction is the only reliable confirmatory test for hemodynamic decompensation in sacubitril-treated patients and clinical examination findings are insufficient to rule out subclinical dysfunction when NT-proBNP is markedly elevated
D) Two major confounders independently elevate NT-proBNP in this patient above what ventricular wall stress alone would produce: CKD (chronic kidney disease; eGFR 44 mL/min/1.73 m²) reduces NT-proBNP renal clearance, raising plasma NT-proBNP independently of cardiac filling pressures; and HFrEF itself maintains chronically elevated NT-proBNP even in a well-compensated patient, reflecting persistent neurohormonal activation at the patient's clinical baseline; the age-adjusted threshold of 900 pg/mL was derived in general populations without CKD and does not apply directly to a patient with CKD and established HFrEF on optimized therapy; the correct interpretation integrates both confounders with a stable clinical examination to conclude that this NT-proBNP level is consistent with this patient's chronic compensated state and does not indicate acute decompensation; the correct clinical action is to continue current management and track the NT-proBNP trend over time rather than act on a single elevated value in isolation
E) NT-proBNP is not affected by sacubitril-valsartan because it is not a neprilysin substrate, making it a valid absolute marker; an NT-proBNP of 3,200 pg/mL unambiguously confirms decompensation in a patient of any age with HFrEF regardless of renal function; the student is correct, and the attending's hesitation reflects unfamiliarity with the role of NT-proBNP as a biomarker that supersedes clinical examination findings in HFrEF monitoring
ANSWER: D
Rationale:
Option D is correct. This question requires integrating three variables simultaneously: the biomarker result, the patient's renal function, and his established HFrEF at clinical baseline. NT-proBNP is not a neprilysin substrate and is unaffected by sacubitril — this correctly distinguishes it from BNP. However, two independent confounders cause NT-proBNP to be chronically elevated above what the age-adjusted diagnostic threshold would predict in this patient. First, CKD: NT-proBNP is eliminated by renal excretion and receptor-mediated clearance; in patients with reduced GFR, renal clearance is impaired and NT-proBNP accumulates at plasma concentrations substantially above those seen in patients with the same cardiac filling pressures but normal renal function. An eGFR of 44 mL/min/1.73 m² represents meaningful CKD-associated NT-proBNP elevation. Second, established HFrEF: patients with chronic HFrEF who are well-compensated on optimized therapy maintain chronically elevated NT-proBNP at their clinical baseline, reflecting the persistent neurohormonal state of the underlying cardiomyopathy even in the absence of acute decompensation. The age-adjusted thresholds (450 pg/mL for under 50; 900 pg/mL for 50-75; 1800 pg/mL for over 75) were derived in heterogeneous emergency department populations presenting with acute dyspnea — not in patients with established HFrEF and CKD on optimized outpatient therapy. The clinically correct approach is to integrate the biomarker with the full clinical picture: stable weight, stable symptoms, no JVP elevation, no rales, no edema. A single NT-proBNP value in isolation, without a comparison to this patient's known chronic baseline NT-proBNP under the same conditions, cannot be reliably interpreted as acute decompensation. The trend over time — rising versus stable — is the clinically actionable interpretation tool.
Option A: Option A is incorrect. The premise that subclinical decompensation detected by natriuretic peptide elevation reliably precedes clinical signs by 48 to 72 hours and mandates urgent diuresis is not supported by evidence in patients with established HFrEF and CKD whose chronic NT-proBNP baseline is elevated by two independent confounders. Acting on a single elevated NT-proBNP without trend data or supportive clinical findings in a clinically stable patient risks iatrogenic volume depletion and prerenal azotemia.
Option B: Option B is incorrect. NT-proBNP is not a neprilysin substrate and is not artifactually elevated by sacubitril-valsartan in the same way BNP is. NT-proBNP remains the valid monitoring biomarker in sacubitril-treated patients precisely because it is neprilysin-independent. The student's error is not in choosing NT-proBNP as the monitoring biomarker but in applying a single age-adjusted threshold without accounting for CKD and chronic HFrEF baseline elevation.
Option C: Option C is incorrect. Echocardiography to assess ejection fraction decline is not mandated by an elevated NT-proBNP alone in a clinically stable patient; clinical examination is a well-validated tool for assessing hemodynamic decompensation in HFrEF, and multiple studies confirm that JVP, S3 gallop, and pulmonary rales correlate reliably with elevated filling pressures. The claim that clinical findings are insufficient when NT-proBNP is markedly elevated in a stable patient misrepresents the role of integrated clinical assessment.
Option E: Option E is incorrect. While NT-proBNP is correctly identified as a valid monitoring biomarker in sacubitril-treated patients, the claim that an NT-proBNP of 3,200 pg/mL "unambiguously confirms decompensation regardless of renal function" ignores the well-established effect of CKD on NT-proBNP clearance and the chronic elevation of NT-proBNP in compensated HFrEF. The NT-proBNP threshold does not supersede clinical examination; integrated assessment is required, and a single NT-proBNP value without trend comparison is insufficient to override a stable clinical picture in a patient with two documented confounders.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.